Fig. 1

Abnormal expression of ESCO2 is associated with poor prognoses in LUAD. a–c ESCO2 mRNA expression in normal lung tissues and LUAD tissues was detected using the Oncomine database. d–f ESCO2 mRNA expression in normal lung tissues and paired LUAD tissues was analyzed based on three LUAD mRNA expression profiling datasets (GSE21933, GSE10072, GSE32863). g and h Patients in the GSE50081 (g) and GSE31210 (h) datasets with high ESCO2 expression had shorter OS. (I) ESCO2 mRNA expression levels were analyzed in normal lung tissues and LUAD tissues from TCGA database. j–l Analysis of TCGA LUAD cohort showed that, compared with patients with low ESCO2 expression levels (the lowest 30%), patients with high ESCO2 mRNA expression (the highest 30%) had higher death rates, shorter disease-free survival, and shorter OS. m and n ESCO2 mRNA (m) and ESCO2 protein (n) expression levels were detected in normal lung tissues and paired LUAD tissues (n = 5)